DE602004007119T2 - 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's - Google Patents

4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's Download PDF

Info

Publication number
DE602004007119T2
DE602004007119T2 DE602004007119T DE602004007119T DE602004007119T2 DE 602004007119 T2 DE602004007119 T2 DE 602004007119T2 DE 602004007119 T DE602004007119 T DE 602004007119T DE 602004007119 T DE602004007119 T DE 602004007119T DE 602004007119 T2 DE602004007119 T2 DE 602004007119T2
Authority
DE
Germany
Prior art keywords
piperidinyl
phenyl
oxy
carbonyl
methylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004007119T
Other languages
German (de)
English (en)
Other versions
DE602004007119D1 (de
Inventor
Mark James GlaxoSmithKl BAMFORD
David Kenneth GlaxoSmithKl DEAN
David Matthew GlaxoSmithKl WILSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602004007119D1 publication Critical patent/DE602004007119D1/de
Application granted granted Critical
Publication of DE602004007119T2 publication Critical patent/DE602004007119T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004007119T 2003-04-10 2004-04-08 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's Expired - Fee Related DE602004007119T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0308333.4A GB0308333D0 (en) 2003-04-10 2003-04-10 Novel compounds
GB0308333 2003-04-10
PCT/EP2004/003985 WO2004089373A1 (en) 2003-04-10 2004-04-08 4- (4-(heterocyclylalkoxy}phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer’s

Publications (2)

Publication Number Publication Date
DE602004007119D1 DE602004007119D1 (de) 2007-08-02
DE602004007119T2 true DE602004007119T2 (de) 2008-02-21

Family

ID=9956580

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004007119T Expired - Fee Related DE602004007119T2 (de) 2003-04-10 2004-04-08 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's

Country Status (22)

Country Link
US (1) US20060205774A1 (enExample)
EP (1) EP1610786B9 (enExample)
JP (1) JP2006522771A (enExample)
KR (1) KR20050111638A (enExample)
CN (1) CN1805747A (enExample)
AR (1) AR044006A1 (enExample)
AT (1) ATE365039T1 (enExample)
AU (1) AU2004228949B2 (enExample)
BR (1) BRPI0409110A (enExample)
CA (1) CA2521899A1 (enExample)
CO (1) CO5640135A2 (enExample)
DE (1) DE602004007119T2 (enExample)
ES (1) ES2288681T3 (enExample)
GB (1) GB0308333D0 (enExample)
IS (1) IS8118A (enExample)
MA (1) MA27726A1 (enExample)
MX (1) MXPA05010816A (enExample)
NO (1) NO20055256L (enExample)
RU (1) RU2005134006A (enExample)
TW (1) TW200503710A (enExample)
WO (1) WO2004089373A1 (enExample)
ZA (1) ZA200507795B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
ES2574014T3 (es) 2005-05-30 2016-06-14 Msd K.K. Derivado de piperidina novedoso
ES2371774T3 (es) * 2005-06-03 2012-01-10 Abbott Laboratories Derivados de ciclobutilamina.
US7635705B2 (en) 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
CA2609957A1 (en) 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1931665A1 (en) 2005-09-20 2008-06-18 Schering Corporation 1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine useful as histamine h3 antagonist
CA2627234A1 (en) 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
PE20071068A1 (es) * 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
AR058558A1 (es) 2005-12-21 2008-02-13 Schering Corp Derivados de anilina sustituida utiles como antagonistas de la histamina h3
CA2634250A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
NZ574873A (en) 2006-07-25 2012-03-30 Cephalon Inc Pyridazinone derivatives as h3 inhibitors
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
BRPI0806473A2 (pt) * 2007-01-22 2011-09-27 Pfizer Prod Inc sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
US20110294836A1 (en) * 2008-06-20 2011-12-01 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
ES2676209T3 (es) 2010-06-23 2018-07-17 Metabolex Inc. Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
KR20140100483A (ko) 2011-12-08 2014-08-14 다이쇼 세이야꾸 가부시끼가이샤 페닐피롤 유도체
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
MX379228B (es) 2013-03-15 2025-03-10 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulación de la hemoglobina.
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
KR20170139064A (ko) 2015-04-21 2017-12-18 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이미다조 이소인돌 유도체, 이의 제조방법 및 이의 의학적 용도
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
BR112021015975A2 (pt) * 2019-03-05 2021-10-05 Eisai R&D Management Co., Ltd. Composto heterocíclico pentacíclico

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
EP0745121B1 (en) * 1992-05-14 2007-06-20 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
DE4407139A1 (de) * 1994-03-04 1995-09-07 Thomae Gmbh Dr K Aryl-1-azacycloalkane und deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
CA2214288C (en) * 1996-09-18 2006-07-18 Lonza Ag Process for the preparation of 1-acyl-4-arylpiperidines
EP0837065A1 (de) * 1996-10-16 1998-04-22 Ciba SC Holding AG Phenylglycidylether-HALS
US6515013B2 (en) * 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
PT1301480E (pt) * 2000-07-13 2007-11-29 Abbott Lab Pirrolidinas 1,3-di-substituídas e 1,3,3-tri-substituídas úteis como ligandos do receptor de histamina-3 e suas aplicações terapêuticas
DK1313721T3 (da) * 2000-08-08 2006-06-26 Ortho Mcneil Pharm Inc Ikke-imidazol-aryloxyalkylaminer som H3-receptorligander
KR20030076716A (ko) * 2001-02-28 2003-09-26 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체
AU2002306848A1 (en) * 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
US7459461B2 (en) * 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases

Also Published As

Publication number Publication date
GB0308333D0 (en) 2003-05-14
TW200503710A (en) 2005-02-01
WO2004089373A1 (en) 2004-10-21
RU2005134006A (ru) 2006-04-10
DE602004007119D1 (de) 2007-08-02
KR20050111638A (ko) 2005-11-25
NO20055256L (no) 2006-01-10
MXPA05010816A (es) 2005-12-05
NO20055256D0 (no) 2005-11-09
EP1610786B1 (en) 2007-06-20
US20060205774A1 (en) 2006-09-14
CA2521899A1 (en) 2004-10-21
CO5640135A2 (es) 2006-05-31
MA27726A1 (fr) 2006-01-02
AU2004228949A1 (en) 2004-10-21
IS8118A (is) 2005-11-08
AU2004228949B2 (en) 2006-11-02
CN1805747A (zh) 2006-07-19
ATE365039T1 (de) 2007-07-15
EP1610786B9 (en) 2008-02-27
JP2006522771A (ja) 2006-10-05
ES2288681T3 (es) 2008-01-16
ZA200507795B (en) 2006-07-26
AR044006A1 (es) 2005-08-24
EP1610786A1 (en) 2006-01-04
BRPI0409110A (pt) 2006-03-28

Similar Documents

Publication Publication Date Title
DE602004007119T2 (de) 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's
DE60309913T2 (de) BICYCLISCHE BENZAMIDVERBINDUNGEN ALS FüR DIE BEHANDLUNG NEUROLOGISCHER KRANKHEITEN GEEIGNETE HISTAMIN-H3-REZEPTORLIGANDEN
DE60106287T2 (de) Chemische verbindungen
CN100415716C (zh) 1-(1,2-双取代哌啶基)-4-取代哌嗪衍生物
AU2004238447B2 (en) Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
DE69719354T2 (de) Muscarin-antagonisten
DE60003702T2 (de) Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
EP2186516B1 (en) Novel benzazepine derivative
US7632829B2 (en) Diazepan derivatives
DE69330823T2 (de) Thiacyclische piperidinylderivate
EA001559B1 (ru) Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперидина как антагонисты рецепторов тахикинина
DE602004008291T2 (de) Substituierte piperidine als histamin-h3-rezeptorliganden
US7638631B2 (en) Methylene dipiperidine derivatives
DE2341965A1 (de) N- eckige klammer auf 1-(omegaphenylalkyl)-piperidyl-4 eckige klammer zu -n-(alpha-pyridyl)-carbonsaeureamide, deren saeureadditionssalze, verfahren zu deren herstellung, sowie deren verwendung als arzneimittel
EP0635505A1 (de) 4-Aryloxy- und 4-Arylthiopiperidin-derivate
DE60112725T2 (de) Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors
US20080009479A1 (en) Tetrahydrobenzazepines as Histamine H3 Receptor Ligands
EP2411363A1 (de) Substituierte piperidine als par-1 antagonisten
DE10256405A1 (de) Neue Verbindungen, die Topoisomerase IV inhibieren
DE3889897T2 (de) 4-Heteropentacyclic-4-N-(phenyl)amido piperidin-Derivate.
WO2004056821A2 (en) Quinolizidine derivatives
AU2007200261A1 (en) Chemokine receptor antagonists and methods of use thereof
MX2008006988A (en) Bradykinin 1 receptor antagonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee